Register
Login:
Share:
Email Facebook Twitter

London South East Natural Resources Briefing webcast: #Emmerson #Alba #Condor Gold #Gold analysis Watch Now

London South East Natural Resources Briefing webcast: #Emmerson #Alba #Condor Gold #Gold analysis
Angus Energy in talks to buy 'transformational' gas asset in North England


Glaxosmithkline Share Chat (GSK)



Share Price: 1,555.00Bid: 1,554.80Ask: 1,555.40Change: 0.00 (0.00%)No Movement on Glaxosmithkline
Spread: 0.60Spread as %: 0.04%Open: 1,544.00High: 0.00Low: 0.00Yesterday’s Close: 1,555.00


Share Discussion for Glaxosmithkline


Thread View

Please login or register to post a message on Share Chat.

Posts per page:

AERRY01
Posts: 105
Opinion:No Opinion
Price:1,498.00
Interesting
3 Dec '18
WILMINGTON, Del.--(BUSINESS WIRE)-- Rigrodsky & Long, P.A.:Do you own shares of TESARO, Inc. (NASDAQ GS: TSRO)?Did you purchase any of your shares prior to December 3, 2018?Do you think the proposed buyout is fair?Do you want to discuss your rights?Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of TESARO, Inc. (“TESARO” or the “Company”) (NASDAQ GS: TSRO) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to be acquired by GlaxoSmithKline plc (“GSK”) (NYSE: GSK) in a transaction valued at approximately $5.1 billion. Under the terms of the agreement, shareholders of TESARO will receive $75.00 in cash for each share of TESARO common stock.If you own common stock of TESARO and purchased any shares before December 3, 2018, if you would like to learn more about this investigation, or if you have any questions concerning this announcement or your rights or interests, please contact Seth D. Rigrodsky or Gina M. Serra toll-free at (888) 969-4242, by e-mail at info@rl-legal.com, or at https://www.rigrodskylong.com/offices-contact.Rigrodsky & Long, P.A., with offices in Delaware, New York, and California, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in numerous cases nationwide, including federal securities fraud actions, shareholder class actions, and shareholder derivative actions.Attorney advertising. Prior results do not guarantee a similar outcome.View source version on businesswire.com: https://www.businesswire.com/news/home/20181203005939/en/Rigrodsky & Long, P.A.Seth D. RigrodskyGina M. Serra(888) 969-4242(302) 295-5310Fax: (302) 654-7530info@rl-legal.comhttp://www.rigrodskylong.comSource: Rigrodsky & Long, P.A.
 
Tom78
Posts: 1,162
Opinion:No Opinion
Price:1,498.00
RE: ????
3 Dec '18
Market thinks they paid over the odds for a high risk company. Only time will tell
bob6
Posts: 788
Opinion:Hold
Price:1,498.00
????
3 Dec '18
TODAY
UNILEVER BUYS HORLICKS PLUS FROM GSK FOR ROUGHLY £3.1bn CASH AND SHARES IN
HINDUSTAN UNILEVER
THEN GSK AGREES TO BUY US -BASED PHARMACEUTICAL GROUP TESARO FOR AROUND £4.6bn

end of the day the sp had dropped 7.62% down 123p ref HL
GOOGLE FINANCE 16.41 GSK 1503.69 AT 16.41 hrs
SO WHY THE BIG DROP TO ME THE NEWS LOOKS GOOD

and of course on the 30/11/18 https://www.fool.co.uk/i...are-price-for-christmas/
Pokerchips
Posts: 7,104
Opinion:No Opinion
Price:1,498.00
RE: When others are fearful, etc
3 Dec '18
Whilst it has fallen nearly 8% today...I think some of that "higher price" was a share that was overbought before it sold off
I cant help but think the share rose ...having seen as a defensive share in a market that has been somewhat volatile..

I am sure some of the sell off has been to jump back into "more risky" shares given the pause in the trade war with China... I mean..it was 1621p on Friday and had risen too fast, too soon ..in my opinion
ge0rge123
Posts: 872
Opinion:Hold
Price:1,498.00
Dontaskme
3 Dec '18
I think you've made a valid Point here.....
It hurts when you were looking at a healthy blue gain this morning to a less than healthy red loss thus evening. Let's hope my last purchase doesn't prove to be a vengeance trade
dontaskme
Posts: 17
Opinion:Hold
Price:1,496.00
Directors Deals
3 Dec '18
The Directors must be excited and positive about these recent deals, as looking at the directors buys you will see they have all recently been buying bundles of shares. Had there been plenty of sells, then you need to be worried. Lets wait and see before everyone jumps ship. Possibly and good time to top up, and 8% drop is excessive, this is what you would expect from an AIM share, not a blue chip 100.
exetrchief
Posts: 419
Opinion:No Opinion
Price:1,496.40
RE: RE: BRAC gene Ovarian/Breast
3 Dec '18
Grayling look at US minnow for other opportunitoes, US Code below
NWBO
exetrchief
Posts: 419
Opinion:No Opinion
Price:1,492.20
RE: RE: BRAC gene Ovarian/Breast
3 Dec '18
Grayling
https://www.biopharmadive.com/news/most-damaging-clinical-trial-failure-astrazeneca-mystic-2017/510924/

And then

AstraZeneca has a lot riding on Lynparza (olaparib). Following a major clinical setback with its PD-L1 inhibitor Imfinzi (durvalumab?), the British pharma and Merck & Co. teamed up in a deal worth potentially $8.5 billion centered on testing combinations of Lynparza and immuno-oncology drugs.

While not focused on combos, SOLO-1 underscores how Lynparza's label could further expand. The drug holds indications for maintenance treatment of adults with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancers who are in a complete or partial response to platinum-based chemotherapy, as well as adult BRCA-mutated advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.

In a statement announcing the new data, Roy Baynes, chief medical officer at Merck Research Laboratories, said his company is working "as quickly as possible" with regulators to get Lynparza approved as first-line maintenance therapy.
iknowverylittle
Posts: 461
Opinion:No Opinion
Price:1,495.20
RE: A good move
3 Dec '18
Feck me, over 8% down now!
longtimeinvestor
Posts: 5,864
Opinion:No Opinion
Price:1,492.80
RE: A good move
3 Dec '18
I sold 12.5% of my shares last week at 1600p. Just found out about todays fall. Looks overdone to me. An hour left today to decide whether to buy back last weeks sale
Grayling
Posts: 1,710
Opinion:Hold
Price:1,493.80
RE: BRAC gene Ovarian/Breast
3 Dec '18
MMmmmm Not sure about getting too excited about PARP inhibitors as this is a crowded marketplace and Astra Zeneca already have significant traction with Lynparza "The PARP inhibitor Lynparza is currently approved in over 60 countries for the treatment of platinum-sensitive relapsed ovarian cancer regardless of BRCA status. It is also approved in several countries, including the US and Japan, for germline BRCAm HER2-negative metastatic breast cancer - regulatory reviews are underway in the EU, Japan and other markets.
DC2007
Posts: 520
Opinion:No Opinion
Price:1,494.80
RE: Acquistion
3 Dec '18
Rare to see this much of a swing in a bluechip in one day - it's gone +/- 7%!
Twonko
Posts: 535
Opinion:No Opinion
Price:1,493.20
When others are fearful, etc
3 Dec '18
Just spent £43,000. It will be the right thing to have done one day. You know it’s true.
exetrchief
Posts: 419
Opinion:No Opinion
Price:1,499.00
RE: Acquistion
3 Dec '18
Took out competitors like AZN , BMS etc.

GSK know how important the pipeline is and how adavnced it is. Study Brac Gene anbd Breat Ovarian, its a massive opportinty to move aheaad of others
Stocktaker01
Posts: 1,327
Opinion:Strong Buy
Price:1,498.80
Well
3 Dec '18
Oversold. 1700 by the new year IMO!
driftking27
Posts: 1,463
Opinion:Hold
Price:1,496.60
RE: Horlicks
3 Dec '18
Heads up, Horlicks is massive India.
iknowverylittle
Posts: 461
Opinion:No Opinion
Price:1,501.80
RE: 713000 buy
3 Dec '18
Showing as a sell at 14.33, 763,413
iknowverylittle
Posts: 461
Opinion:No Opinion
Price:1,504.40
RE: 713000 buy
3 Dec '18
at approx. 14.40....
iknowverylittle
Posts: 461
Opinion:No Opinion
Price:1,508.60
713000 buy
3 Dec '18
Did anyone else just see a huge 713000 buy or was it my pc playing tricks on me?
russ1983
Posts: 45
Opinion:No Opinion
Price:1,505.40
Acquistion
3 Dec '18
they`ve paid 110% premium?! ...why pay so much for it
exetrchief
Posts: 419
Opinion:No Opinion
Price:1,505.40
BRAC Gene Ovarian /Breast
3 Dec '18
Something no broker or institutional investor would not be able to iunderstand.

Huge asset for GSK, and one that is worth a dam site more than they paid, as results will show in the next 3 years

GSK also believes PARP inhibitors offer significant opportunities for use in the treatment of multiple cancer types. In addition to ovarian cancer, Zejula is currently being investigated for use as a possible treatment in lung, breast and prostate cancer, both as a monotherapy and in combination with other medicines, including with TESARO's own anti-PD-1 antibody (dostarlimab, formerly known as TSR-042).

In addition to Zejula, TESARO has several oncology assets in its pipeline including antibodies directed against PD-1, TIM-3 and LAG-3 targets.
Exoplanet
Posts: 33
Opinion:No Opinion
Price:1,496.60
RE: The big fall
3 Dec '18
i would hope there's a good pipeline at tesaro that could be realised with GSK's expertise backing it. However i do think the BoDs approach/decision has to questioned somewhat. Since the rumours kicked in the stocks jumped from around $27 to around $46 at the close of 30nov, and now GSk are offering $75.
Dinoken
Posts: 756
Opinion:No Opinion
Price:1,509.60
RE: Re: The big fall
3 Dec '18
Sold Horlicks too cheap as well. Believe everybody had 3.5-4 bill pencilled in.
Bobsto12
Posts: 43
Opinion:No Opinion
Price:1,531.40
RE: Re: The big fall
3 Dec '18
Market reaction tells you everything you need to know about the price. Whatever the long term benefits its hard to imagine it couldn't be acquired at a much lower premium. Doesn't say much for ceo negotiating skills. Same old story re acquisitions...borrow too much to overpay and in the long term a new ceo writes it all off.
bob6
Posts: 788
Opinion:No Opinion
Price:1,526.00
Horlicks
3 Dec '18
who drinks it i had a cup in 1954
time to buy no not hollicks GSK




Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk









Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.